Fig. 1From: Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance studyInformation component and its 95% credibility interval over time for (a) neuromuscular junction disorders, (b) encephalitis/myelitis, (c) Guillain-Barre Syndrome, and (d) meningitisBack to article page